- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 91,140 | 25.06.24 17:05:23 | +0,350 | +0,39% | 91,120 | 91,170 | 90,870 | 90,790 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 986,000 | 25.06.24 08:13:49 | +1,400 | +0,14% | 1.005,000 | 1.010,500 | 986,000 | 984,600 |
